SG11201808388QA - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith - Google Patents
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewithInfo
- Publication number
- SG11201808388QA SG11201808388QA SG11201808388QA SG11201808388QA SG11201808388QA SG 11201808388Q A SG11201808388Q A SG 11201808388QA SG 11201808388Q A SG11201808388Q A SG 11201808388QA SG 11201808388Q A SG11201808388Q A SG 11201808388QA SG 11201808388Q A SG11201808388Q A SG 11201808388QA
- Authority
- SG
- Singapore
- Prior art keywords
- san diego
- international
- compositions
- co7d
- methods
- Prior art date
Links
- -1 aminopurine compounds Chemical class 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003306 harvesting Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662317412P | 2016-04-01 | 2016-04-01 | |
| PCT/US2017/025252 WO2017173206A1 (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808388QA true SG11201808388QA (en) | 2018-10-30 |
Family
ID=59959573
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808388QA SG11201808388QA (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| SG10202009589UA SG10202009589UA (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202009589UA SG10202009589UA (en) | 2016-04-01 | 2017-03-31 | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10576085B2 (https=) |
| EP (1) | EP3436018A4 (https=) |
| JP (1) | JP7014731B2 (https=) |
| KR (1) | KR102356433B1 (https=) |
| CN (1) | CN109069512B (https=) |
| AU (1) | AU2017241837B2 (https=) |
| BR (1) | BR112018070163A2 (https=) |
| CA (1) | CA3018986A1 (https=) |
| CL (1) | CL2018002787A1 (https=) |
| EA (1) | EA039392B1 (https=) |
| IL (1) | IL262007B2 (https=) |
| MX (1) | MX379513B (https=) |
| NZ (1) | NZ746554A (https=) |
| SG (2) | SG11201808388QA (https=) |
| WO (1) | WO2017173206A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201116559D0 (en) | 2011-09-26 | 2011-11-09 | Univ Leuven Kath | Novel viral replication inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| JOP20160086B1 (ar) | 2015-05-08 | 2021-08-17 | 2 Katholieke Univ Leuven Ku Leuven Research And Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20160198B1 (ar) | 2015-09-16 | 2022-03-14 | Janssen Pharmaceuticals Inc | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JO3633B1 (ar) | 2015-09-16 | 2020-08-27 | Katholieke Univ Leuven Ku Leuven Research & Development | مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| BR112018068676A2 (pt) | 2016-03-31 | 2019-01-15 | Janssen Pharmaceuticals Inc | derivados de indol substituídos como inibidores da replicação viral do dengue |
| BR112018069601A2 (pt) | 2016-03-31 | 2019-01-29 | Janssen Pharmaceuticals Inc | derivados de indolina substituídos como inibidores da replicação viral da dengue |
| HUE056631T2 (hu) | 2016-04-01 | 2022-02-28 | Signal Pharm Llc | (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik |
| BR112018068956A2 (pt) | 2016-04-01 | 2019-01-22 | Janssen Pharmaceuticals Inc | derivados do composto indol substituídos como inibidores da replicação viral da dengue |
| JOP20170069B1 (ar) | 2016-04-01 | 2021-08-17 | 1 Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180025B1 (ar) | 2017-03-31 | 2021-08-17 | Janssen Pharmaceuticals Inc | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| JOP20180026A1 (ar) | 2017-03-31 | 2019-01-30 | Univ Leuven Kath | مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك |
| UA125970C2 (uk) | 2017-05-22 | 2022-07-20 | Янссен Фармасьютікалз, Інк. | Заміщені похідні індоліну як інгібітори реплікації вірусів денге |
| EP3630723B1 (en) | 2017-05-22 | 2022-08-24 | Janssen Pharmaceuticals, Inc. | Substituted indoline derivatives as dengue viral replication inhibitors |
| AU2018345647A1 (en) | 2017-10-04 | 2020-04-16 | Celgene Corporation | Compositions and methods of use of cis-4-(2-{((3S,4R)-3-fluorooxan-4-yl) amino}-8-(2,4,6-trichloroanilino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide |
| PE20210096A1 (es) | 2018-04-03 | 2021-01-12 | Blueprint Medicines Corp | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret |
| EP3833372A4 (en) * | 2018-08-10 | 2022-06-08 | Blueprint Medicines Corporation | TREATMENT OF EGFR MUTANT CANCER |
| MX2021012638A (es) * | 2019-04-16 | 2022-01-04 | Vivace Therapeutics Inc | Compuestos biciclicos. |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| WO2021102204A1 (en) * | 2019-11-20 | 2021-05-27 | Vivace Therapeutics, Inc. | Heteroaryl compounds |
| EP4157829A1 (en) | 2020-05-29 | 2023-04-05 | Blueprint Medicines Corporation | Solid forms of pralsetinib |
| TW202202498A (zh) * | 2020-07-01 | 2022-01-16 | 大陸商四川海思科製藥有限公司 | 一種並環雜環衍生物及其在醫藥上的應用 |
| KR102664454B1 (ko) * | 2021-08-03 | 2024-05-09 | 한국생명공학연구원 | 젬시타빈에 대한 민감성 향상을 위한 신규 표적 및 이의 활용 |
| CN114681456A (zh) * | 2022-02-23 | 2022-07-01 | 中山大学附属第六医院 | Plx3397在结直肠癌的治疗中的用途 |
| EP4703725A1 (en) | 2024-08-29 | 2026-03-04 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Modulators of the mitotic cell cycle in cancer cells and uses thereof for the treatment of cancer |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| FI109088B (fi) | 1997-09-19 | 2002-05-31 | Leiras Oy | Tabletti ja menetelmä sen valmistamiseksi |
| AU2004309420B2 (en) * | 2003-12-23 | 2008-10-30 | Novartis Ag | Bicyclic heterocyclic p-38 kinase inhibitors |
| US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| US7759342B2 (en) | 2005-01-13 | 2010-07-20 | Signal Pharmaceuticals, Llc | Methods of treatment and prevention using haloaryl substituted aminopurines |
| US7723340B2 (en) | 2005-01-13 | 2010-05-25 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
| WO2007030438A2 (en) * | 2005-09-06 | 2007-03-15 | Pharmacopeia, Inc. | Aminopurine derivatives for treating neurodegenerative diseases |
| WO2007062338A2 (en) | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Solid formulations |
| WO2007134298A2 (en) | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| CA2667345C (en) | 2006-10-27 | 2016-03-22 | Signal Pharmaceuticals, Llc | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith |
| ES2400006T3 (es) | 2008-04-23 | 2013-04-04 | Farmasierra Manufacturing, S.L. | Formulación farmacéutica mejorada a base de ibuprofeno y codeína |
| WO2011071491A1 (en) | 2009-12-09 | 2011-06-16 | Signal Pharmaceuticals, Llc | Isotopologues of 4-[9-(tetrahydro-furan-3-yl)-8-(2, 4, 6- trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol |
| US8603527B2 (en) | 2010-10-25 | 2013-12-10 | Signal Pharmaceuticals, Llc | Pharmaceutical formulations of a substituted diaminopurine |
| US8680076B2 (en) * | 2010-10-25 | 2014-03-25 | Signal Pharmaceuticals, Llc | Methods of treatment, improvement and prevention using haloaryl substituted aminopurines |
| US9466042B2 (en) | 2012-01-24 | 2016-10-11 | International Business Machines Corporation | Facilitating the design of information technology solutions |
| US20160082015A1 (en) | 2013-04-18 | 2016-03-24 | President And Fellows Of Harvard College | Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders |
| GB201321737D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| US9512124B2 (en) * | 2014-10-06 | 2016-12-06 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| CN115131834A (zh) * | 2015-08-13 | 2022-09-30 | 小米科技有限责任公司 | 移动设备及其屏幕模组、指纹采集方法、装置及电子设备 |
| HUE056631T2 (hu) * | 2016-04-01 | 2022-02-28 | Signal Pharm Llc | (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahidro-2H-PIRÁN-4-il)amino)-8-((2,4,6-triklorofenil)amino)-9H-purin- 9-il)-1-metil-ciklohexán-1-karboxamid és alkalmazási módszereik |
-
2017
- 2017-03-31 MX MX2018011992A patent/MX379513B/es unknown
- 2017-03-31 KR KR1020187028514A patent/KR102356433B1/ko active Active
- 2017-03-31 SG SG11201808388QA patent/SG11201808388QA/en unknown
- 2017-03-31 EP EP17776735.7A patent/EP3436018A4/en not_active Withdrawn
- 2017-03-31 US US15/475,899 patent/US10576085B2/en active Active
- 2017-03-31 IL IL262007A patent/IL262007B2/en unknown
- 2017-03-31 AU AU2017241837A patent/AU2017241837B2/en active Active
- 2017-03-31 WO PCT/US2017/025252 patent/WO2017173206A1/en not_active Ceased
- 2017-03-31 CN CN201780021651.0A patent/CN109069512B/zh active Active
- 2017-03-31 JP JP2018551358A patent/JP7014731B2/ja active Active
- 2017-03-31 SG SG10202009589UA patent/SG10202009589UA/en unknown
- 2017-03-31 BR BR112018070163A patent/BR112018070163A2/pt not_active Application Discontinuation
- 2017-03-31 EA EA201892229A patent/EA039392B1/ru unknown
- 2017-03-31 CA CA3018986A patent/CA3018986A1/en not_active Abandoned
- 2017-03-31 NZ NZ746554A patent/NZ746554A/en unknown
-
2018
- 2018-09-28 CL CL2018002787A patent/CL2018002787A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7014731B2 (ja) | 2022-02-01 |
| BR112018070163A2 (pt) | 2019-01-29 |
| MX2018011992A (es) | 2019-01-24 |
| KR20180126497A (ko) | 2018-11-27 |
| MX379513B (es) | 2025-03-11 |
| EA201892229A1 (ru) | 2019-03-29 |
| CN109069512A (zh) | 2018-12-21 |
| NZ746554A (en) | 2023-03-31 |
| EA039392B1 (ru) | 2022-01-21 |
| AU2017241837B2 (en) | 2021-07-22 |
| CN109069512B (zh) | 2022-06-14 |
| CA3018986A1 (en) | 2017-10-05 |
| JP2019510066A (ja) | 2019-04-11 |
| CL2018002787A1 (es) | 2019-01-18 |
| EP3436018A4 (en) | 2019-11-13 |
| WO2017173206A1 (en) | 2017-10-05 |
| IL262007B (en) | 2022-12-01 |
| IL262007A (en) | 2018-10-31 |
| IL262007B2 (en) | 2023-04-01 |
| SG10202009589UA (en) | 2020-10-29 |
| US20170281633A1 (en) | 2017-10-05 |
| KR102356433B1 (ko) | 2022-01-27 |
| US10576085B2 (en) | 2020-03-03 |
| EP3436018A1 (en) | 2019-02-06 |
| AU2017241837A1 (en) | 2018-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808388QA (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| SG11201808003RA (en) | Bromodomain inhibitors | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201810525XA (en) | Anti-gitr antibodies and uses thereof | |
| SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201808125RA (en) | Methods for solid tumor treatment | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201903193WA (en) | Deodorant comprisng a zinc carboxylate salt and aluminium chlorohydrate | |
| SG11201909513QA (en) | Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201809537VA (en) | Urea motif containing compounds and derivatives thereof as antibacterial drugs |